FRANKFURT (dpa-AFX) - The good run since the beginning of May pushed Evotec shares on Friday to their highest level since September. The drug discovery company's shares recently rose 2.2 percent following news that the company had received receivables funding. $1.7 million was paid by philanthropic backer Open Philanthropy to help Evotec advance the discovery of RNA-based therapies against henipaviruses.

Since the May low of 15.38 euros, the Evotec share price has now gained almost 40 percent. The cyber attack that became known in April, as a result of which the share had to leave the MDax due to a delayed annual report, has long since been made up for in terms of the share price.

When Deutsche Borse decides on its index compositions this Monday, Evotec is expected to return to the mid-cap index. Since the annual report is available in the meantime, nothing stands in the way of a reinstatement. The change would then take effect on June 19./tih/jha/